Clinical trials sponsored by Shandong Cancer Hospital and Institute

Phase breakdown

Conditions studied

Recruiting trials led by Shandong Cancer Hospital and Institute

• Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
  NCT06844422 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
  NCT06778382 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
  NCT07600268 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
  NCT06356584 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer
  NCT07408505 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury
  NCT06847555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
  NCT06050317 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Shandong Cancer Hospital and Institute recruiting for?

Shandong Cancer Hospital and Institute is the lead sponsor of 7 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.